PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-

Completed

Conditions: Adult Not Younger Than 65 Years

First Posted Date: 2017-01-09

Last Posted Date: 2023-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 696

Registration Number: NCT03014206

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Phase 1

Completed

Conditions: Lyme Borreliosis, Nervous System

Interventions: Biological: VLA15 without Alum
Biological: VLA15 with Alum

First Posted Date: 2017-01-04

Last Posted Date: 2023-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 179

Registration Number: NCT03010228

Locations: 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
🇺🇸
eStudySite, La Mesa, California, United States

and more 2 locations

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Phase 3

Completed

Conditions: Arthritis Juvenile Idiopathic

First Posted Date: 2016-12-22

Last Posted Date: 2025-06-03

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT03000439

Locations: 🇩🇪
St. Josef-Stift Sendenhorst, Sendenhorst, Germany
🇭🇺
Semmelweis Egyetem, Budapest, Hungary
🇮🇳
Nirmal Hospital Pvt Ltd, Surat, Gujarat, India

and more 47 locations

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: PF-06650833
Drug: Placebo
Drug: Tofacitinib

First Posted Date: 2016-12-19

Last Posted Date: 2020-02-27

Lead Sponsor: Pfizer

Target Recruit Count: 269

Registration Number: NCT02996500

Locations: 🇺🇸
Arthritis & Rheumatic Care Center, South Miami, Florida, United States
🇺🇸
Medical Associates of North Georgia, Canton, Georgia, United States
🇺🇸
Millennium Research, Ormond Beach, Florida, United States

and more 96 locations

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Talazoparib

First Posted Date: 2016-12-19

Last Posted Date: 2021-01-05

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT02997163

Locations: 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States

and more 6 locations

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Talazoparib

First Posted Date: 2016-12-19

Last Posted Date: 2021-02-25

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT02997176

Locations: 🇺🇸
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States

and more 8 locations

Korean Post-marketing Surveillance for Xeljanz

Completed

Conditions: Rheumatoid Arthritis
Psoriatic Arthritis

First Posted Date: 2016-12-06

Last Posted Date: 2024-08-27

Lead Sponsor: Pfizer

Target Recruit Count: 1041

Registration Number: NCT02984020

Locations: 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Kyung Hee University Hospital at Gangdong / Rheumatology, Seoul, Gangdong-gu, Korea, Republic of
🇰🇷
Chonbuk National University Hospital, Department of Rheumatology, Chonju, Chonbuk, Korea, Republic of

and more 43 locations

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Drug: Placebo
Drug: PF-06700841

First Posted Date: 2016-11-29

Last Posted Date: 2020-05-26

Lead Sponsor: Pfizer

Target Recruit Count: 142

Registration Number: NCT02974868

Locations: 🇺🇸
Yale Hearing and Balance Center, New Haven, Connecticut, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

and more 52 locations

PF-06741086 Multiple Dose Study in Severe Hemophilia

Phase 2

Completed

Conditions: Hemophilia A or B

Interventions: Biological: PF-06741086

First Posted Date: 2016-11-29

Last Posted Date: 2019-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT02974855

Locations: 🇨🇱
Hospital Dr. Sotero del Rio, Santiago, Chile
🇭🇷
Klinicki bolnicki centar Zagreb, Zagreb, Croatia
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 7 locations

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: PF-06835919
Other: Placebo

First Posted Date: 2016-11-28

Last Posted Date: 2017-12-15

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT02974374

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy